Ann: Race-Chaim Sheba FTO Biomarker Collaboration, page-122

Biomarker program was measuring everything to do with FTO and Zantrene for Sheba 2 phase 1b/2. Given Phase 1b is wrapped up and into phase 2 with readouts due h1 2023, I am assuming FTO as a biomarker is known.

If this was not the case, would this be required to be announced? One could say that solid tumour platform screening is a last ditch effort to provide proof of concept. By taking the AGM comments from DrT that he is right and Phil is wrong on the bigger opportunity or whale, gives me peace of mind.

This gives me some comfort that it is just dotting the i and crossing the t’s to ensure systematically gone through all tumour response and synergy to Zantrene. It is likely data gathering for market analysis and data package for Pharma.

The risk is in translating into the clinic which I think is derisked as much as possible, but DYOR. If FTO is not translatable, some very smart people have wasted what I have calculated to be over 1 million hours collectively.

This is besides the 50+ clinical trials and ~$500m in todays money + previously approved in France. Not much more to do than wait out the results in 2023, hopefully some surprises and then unravel the commercial strategy.

Have discussions with Astex raised the topic of which other cancers and drugs in their pipeline might synergise with Zantrene / FTO inhibitor? Is this a driver for pan-tumour screening.